N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Children's Hospital Los Angeles
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Nant Operations Center, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT00295919
First received: February 23, 2006
Last updated: December 18, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Publications:
Marachelian A, Kang MH, Hwang K, et al.: Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-10009, 2009.